XERS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

81.38M

+35.42%

0.003

-103.03%

83.23M

+38.45%

0.022

-172.23%

92.63M

+29.49%

0.003

-105.55%

Estimates Revision

The market is revising Upward the revenue expectations for Xeris Biopharma Holdings, Inc. (XERS) for FY2025, with the revenue forecasts being adjusted by 0.33% over the past three months. During the same period, the stock price has changed by -0.75%.

Revenue Estimates for FY2025

Revise Upward

+0.33%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+22.23%

In Past 3 Month

Stock Price

Go Down

-0.75%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast XERS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XERS is 12.33 USD with a low forecast of 9.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

9.00

Averages

12.33

High

18.00

Current: 0.000

Low

9.00

Averages

12.33

High

18.00

Barclays

Overweight

initiated

2025-12-08

Reason

Barclays

Price Target

2025-12-08

initiated

Overweight

Reason

Barclays initiated coverage of Xeris Biopharma with an Overweight rating and $9 price target. The firm rolled out coverage on the specialty pharmaceuticals industry with a neutral view, saying investor sentiment is improving as companies shift focus to innovation, margin expansion and de-leveraging. The group's pricing headwinds are easing while debt leverage is coming down, the analyst tells investors in a research note. Barclays sees "plenty of opportunity" as the sector "remains in a transition phase."

Piper Sandler

David Amsellem

Neutral

maintain

$6 -> $8

2025-11-07

Reason

Piper Sandler

David Amsellem

Price Target

$6 -> $8

2025-11-07

maintain

Neutral

Reason

Piper Sandler analyst David Amsellem raised the firm's price target on Xeris Biopharma to $8 from $6 and keeps a Neutral rating on the shares. The firm notes Xeris reported a Q3 net earnings per share of 0c on total revenues of $74.4M, compared to Street estimates of 1c and $74.2M, respectively. Notably, Recorlev continues to benefit from an expanding hypercortisolism space, positioning the company for sustainable cash generation, Piper adds.

Oppenheimer

Leland Gershell

Outperform

maintain

$8 -> $18

2025-10-29

Reason

Oppenheimer

Leland Gershell

Price Target

$8 -> $18

2025-10-29

maintain

Outperform

Reason

Oppenheimer analyst Leland Gershell raised the firm's price target on Xeris Biopharma to $18 from $8 and keeps an Outperform rating on the shares. Motivated by bullish commentary from the firm's recent endocrinologist expert call, Oppenheimer has revised its Xeris model to include value contribution from the company's subcutaneous levothyroxine candidate. XP-8121 is slated to enter a Phase 3 hypothyroidism trial in the first half of 2026, and the firm believes this once-weekly injectable's favorable Phase 2 performance derisks remaining development. Oppenheimer forecasts $1.3B peak sales, as may be generated from just 5% uptake into our estimated 2.6M U.S. adults with poorly controlled hypothyroidism following anticipated launch in the 2030 timeframe. It expects XP-8121's progress toward commercialization along with continued commercial execution to drive outperformance.

H.C. Wainwright

Buy

initiated

$10

2025-08-12

Reason

H.C. Wainwright

Price Target

$10

2025-08-12

initiated

Buy

Reason

H.C. Wainwright assumed coverage of Xeris Biopharma with a Buy rating and $10 price target. The firm believes the commercial potential of the company's commercial portfolio remains "meaningfully underappreciated." The portfolio has the potential to drive further Xeris stock appreciation, the analyst tells investors in a research note.

Oppenheimer

Outperform

maintain

$7 -> $8

2025-08-08

Reason

Oppenheimer

Price Target

$7 -> $8

2025-08-08

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on Xeris Biopharma to $8 from $7 and keeps an Outperform rating on the shares following quarterly results. The firm cites outlook for continued commercial execution and sustainable growth.

Oppenheimer

Outperform

maintain

$6 -> $7

2025-05-09

Reason

Oppenheimer

Price Target

$6 -> $7

2025-05-09

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on Xeris Biopharma to $7 from $6 and keeps an Outperform rating on the shares. The firm notes the company reported Q1 total revenue of $60.1M, which topped OpCo/consensus estimates on solid Recorlev/Gvoke performance and Keveyis durability. Management tightened full-year guidance to $260M-$275M from $255M-$275M, and the firm expects adjusted EBITDA to be consistently positive going forward. No apparent tariff threat as manufacturing is wholly domestic. Oppenheimer looks forward to the June 3 analyst day at which a key focus will be the company's subcutaneous levothyroxine for hypothyroidism.

Valuation Metrics

The current forward P/E ratio for Xeris Biopharma Holdings Inc (XERS.O) is 60.39, compared to its 5-year average forward P/E of -6.90. For a more detailed relative valuation and DCF analysis to assess Xeris Biopharma Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.90

Current PE

60.39

Overvalued PE

33.41

Undervalued PE

-47.21

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-13.92

Current EV/EBITDA

24.10

Overvalued EV/EBITDA

95.81

Undervalued EV/EBITDA

-123.64

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

2.16

Current PS

3.41

Overvalued PS

2.93

Undervalued PS

1.40

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 259.68% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 259.68% over the last month.

Sold

Bought

XERS News & Events

Events Timeline

No data

News

9.5

01-08Newsfilter

PinnedXeris Anticipates 2025 Revenue of $292 Million, Exceeding Guidance

2.0

01-02Benzinga

Outlook Therapeutics Inc Faces 60.9% Drop After FDA Response on ONS-5010

9.5

01-01Fool

Xeris Biopharma Shares Surge 7.59% as Competitor Corcept's FDA Approval Fails

People Also Watch

Frequently Asked Questions

What is Xeris Biopharma Holdings Inc (XERS) stock price today?

The current price of XERS is 7.93 USD — it has decreased -2.46 % in the last trading day.

What is Xeris Biopharma Holdings Inc (XERS)'s business?

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company focused on improving patient lives by developing and commercializing products across a range of therapies. It has three commercially available products: Recorlev, Gvoke, and Keveyis. Recorlev is for the treatment of endogenous Cushing’s syndrome. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is a therapy for primary periodic paralysis. It also has a pipeline of development programs led by XP-8121, a phase III-ready, once-weekly subcutaneous injection for hypothyroidism. It is pursuing formulation and development partnerships to apply its XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies’ proprietary drugs and biologics. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.

What is the price predicton of XERS Stock?

What is Xeris Biopharma Holdings Inc (XERS)'s revenue for the last quarter?

Xeris Biopharma Holdings Inc revenue for the last quarter amounts to 74.38M USD, increased 37.06 % YoY.

What is Xeris Biopharma Holdings Inc (XERS)'s earnings per share (EPS) for the last quarter?

Xeris Biopharma Holdings Inc. EPS for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

What changes have occurred in the market's expectations for Xeris Biopharma Holdings Inc (XERS)'s fundamentals?

How many employees does Xeris Biopharma Holdings Inc (XERS). have?

Xeris Biopharma Holdings Inc (XERS) has 394 emplpoyees as of January 10 2026.

What is Xeris Biopharma Holdings Inc (XERS) market cap?

Today XERS has the market capitalization of 1.32B USD.